Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Repare Therapeutics Inc. - Common Shares (NQ:RPTX)

2.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
24 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors ↗
 
Via Benzinga
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million. 
Via Benzinga
News headline image
30 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday. 
Via Benzinga
News headline image
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
From Repare Therapeutics Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
News headline image
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients ↗
Repare Therapeutics Inc (NASDAQ: RPTX) has announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR trial of RP-3500.... 
Via Benzinga
News headline image
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
News headline image
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Repare Therapeutics Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
News headline image
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Proposed Public Offering of Common Shares
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
From Repare Therapeutics Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.